Subclinical inflammation biomarkers in an infant-juvenile patients with type 1 diabetes

Authors

  • Adela Abregú Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán, Tucumán, Argentina
  • Teresita Carrizo Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán, Tucumán, Argentina
  • Elba Díaz Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán, Tucumán, Argentina
  • Cristina Fonio Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán, Tucumán, Argentina
  • Cristina Bazán Hospital of the Child Jesus, Tucumán, Argentina

DOI:

https://doi.org/10.47196/diab.v49i2.199

Keywords:

diabetes, subclinic inflammation, proinflammatory cytokines, hspcr

Abstract

Type 1 diabetes (T1D) is associated with an increased risk of vascular complications. Proinflammatory cytokines IL-6, MCP-1 and TNF-α, have been implicated in the development of these complications.

The aim of this study was to determine the plasma levels of IL-6, MCP-1, TNF-α, hsPCR and fibrinogen (Fg) in patients with infant-juvenile DT1 and its association with the glycemic control degree and time to progression of disease.

Forty-five DT1 patients (24 m/21 w), age 11,2±1,8 years, with a time to progression of disease of 3,1±3,0 years, without vascular complications, were studied and compared with 20 healthy subjects. Plasma levels of IL-6, MCP-1 and TNF-α, Fg, hsPCR, leukocyte count, fasting blood glucose and HbA1c were determined. The presence of retinopathy and nephropathy was rule out. Data were analyzed with the Windows software SPSS 15. Diabetic children had higher levels of IL-6 (1,10±0,74 vs 0,68±0,19 pg/ml; p=0,005), MCP-1 (130±49 vs 95±18 pg/ml, p=0,02), hsPCR (1,02±1,07 vs 0,43 ±026 mg/l; p=0,007) Fg (299±59 vs 246±18 mg/dl, p=0,0001) with respect to controls. No significant difference of TNF-α between both groups were observed. When diabetic patients were grouped according to glycemic control degree (HbA1c <8% and ≥8%) and time to progression of DT1 (≤3 and >3 years), no significant differences were found in the molecules studied. In diabetic patients, HbA1c was correlated with IL-6, MCP-1 and hsPCR.

These results reflect a proinflammatory state in the diabetic population studied.

Author Biographies

Adela Abregú, Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán, Tucumán, Argentina

Dr. in Biochemistry; Prof. Asoc. Professional Practice, Chair of Professional Practice, Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán

Teresita Carrizo, Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán, Tucumán, Argentina

Biochemistry; Professional Practice Teacher, Chair of Professional Practice, Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán

Elba Díaz, Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán, Tucumán, Argentina

Biochemistry; Prof. Asoc. Professional Practice, Chair of Professional Practice, Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán

Cristina Fonio, Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán, Tucumán, Argentina

Biochemistry; Professional Practice Teacher, Chair of Professional Practice, Faculty of Biochemistry, Chemistry and Pharmacy, National University of Tucumán

Cristina Bazán, Hospital of the Child Jesus, Tucumán, Argentina

Dr. in Medicine; Head of the Endocrinology Service of the Hospital del Niño Jesús, Provincial Health System (SIPROSA)

References

Snell-Bergeon JK, West NA, Mayer-Davis EJ, et al. Inflammatory markers are increased in youth with type 1 diabetes: The SEARCH Case-Control Study. J. Clin. Endocrinol Metab. 2010; 95(6):2868-76.

Fujii C, Sakakibara H, Kondo, et al. Plasma fibrinogen levels and cardiovascular risk factors in Japanese schoolchildren. J. Epidemiol. 2006; 16:64-9.

Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diabetes Vasc. Dis. Res. 2007; 4:84-8.

Croker BA, Kiu H, Pellegrini M, et al. IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunol. Cell Biol. 2012; 90(1):124-9.

Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond) 2012; 122:143-59.

Geerlings SE, Brouwer EC, Van Kessel KC, et al. Cytokine secretion is impaired in women with diabetes mellitus. Eur. J. Clin. Invest. 2000; 30(11):995-1001.

Targher G, Zenari L, Bertolini L, et al. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 2001; 24(5):956-7.

Jialal I, Kaur H. The role of toll-like receptors in diabetes induced inflammation: implications for vascular complications. Current Diabetes Reports 2013; 12(2):172-9.

Wegner M, Araszkiewicz A, Piorunska-Stolzmann M, et al. Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation 2013; 36(3):723-8.

Kusano KF, Nakamura K, Kusano H, et al. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ. J. 2004; 68(7):671-6.

Sozer V, Himmetoglu S, Korkmaz GG, et al. Paraoxonase, oxidized low density lipoprotein, monocyte chemoattractant protein-1 and adhesion molecules are associated with macrovascular complications in patients with type 2 diabetes mellitus. Minerva Med. 2014; 105(3):237-44.

Ikeda U, Matsui K, Murakami Y, et al Monocyte chemoattractant protein-1 and coronary artery disease. Clin. Cardiol. 2002; 25(4):143-7.

Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 2002; 16:163-70.

Fernando Gomes DF, Telo HP, Souza JCN, et al. Obesidad y enfermedad arterial coronaria: papel de la inflamación vascular. Arq. Bras. Cardiol. 2010; 94:260-6.

Du Clos TW. Pentraxins: structure, function, and role in Inflammation. ISRN Inflamm. 2013; 2013:379040. doi:10.1155/2013/379040.

Montgomery JE, Brown JR. Metabolic biomarkers for predicting cardiovascular disease. Vasc. Health Risk Manag. 2013; 9:37-45.

Ahmed MS, Jadhav AB, Hassan A, et al. Acute phase reactants as novel predictors of cardiovascular disease. ISRN Inflamm 2012; 2012:953461. doi:10.5402/2012/953461.

Babar GS, Zidan H, Widlansky ME, et al. Impaired endothelial function in preadolescent children with type 1 diabetes. Diabetes Care 2011; 34(3):681-5.

Cé GV, Rohde LE, da Silva AM, et al. Endothelial dysfunction is related to poor glycemic control in adolescents with type 1 diabetes under 5 years of disease: evidence of metabolic memory. J. Clin. Endocrinol. Metab. 2011; 96(5):1493-9.

Bayir O, Korkmaz HA, Dizdarer C, et al. Carotid artery intima-media thickness in pediatric type 1 diabetic patients. Anadolu Kardiyol Derg. 2014; doi: 10.5152/akd.2014.4788.

Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation indevelopment of diabetes and its complications. J. Clin. Endocrinol. Metab. 2009; 94(9):3171-82.

Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pract. 2014; 105(2):141-50.

Fawaz L, Elwan AE, Kamel YH, et al. Value of C-reactive protein and IL-6 measurements in type 1 diabetes mellitus. Arch. Med. Sci. 2009; 5(3):383-90.

Picardi MG, Valorani U, Vespasiani Gentilucci V, et al. Raised C-reactive protein levels in patients with recent onset type1 diabetes. Diabetes Metab. Res. Rev. 2007; 23:211-4.

Scholin A, Siegbahn A, Lind L, et al. CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell function during the first year after diagnosis of type 1 diabetes. Diabetes Metab. Res. Rev. 2004; 20(3):205-10.

Ihm CG, Park JK, Hong SP, et al. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 1998; 79:33-7.

Panee J. Monocyte chemo attractant protein 1 (MCP-1) in obesity and diabetes. Cytokine 2012; 60(1):1-12.

Kravchun P, Narizhna A, Ryndina N. Monocyte chemo attractant protein-1 in patients with chronic heart failure of different functional class with type 2 diabetes. Georgian Med. News 2014; 231:42-5.

Verrijn Stuart AA, Schipper HS, Tasdelen I, et al. Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes. J. Clin. Endocrinol. Metab 2012; 97(2):463-72.

Zineh I, Beitelshees AL, Silverstein JH, et al. Serum monocyte chemo attractant protein-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1 diabetes. Diabetes Care 2009; 32(3):465-7.

Romano M, Pomilio M, Vigneri S, et al. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes Care 2001; 24(9):674-8.

Arroyo V, Camacho P, Vásquez K, et al. Marcadores de inflamación y autoinmunidad en pacientes con diabetes tipo 1. Rev. Chile Endocrinol. Diabetes 2014; 7:6-9.

Amanullah S, Jarari A, Govindan M, et al. Association of hs-CRP with diabetic and non-diabetic individuals. JJBS 2010; 3:7-12.

Targher G, Bertolini L, Zoppini G, et al. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diab. Med. 2005; 22:999-1004.

Downloads

Published

2023-01-10

How to Cite

Abregú, A., Carrizo, T., Díaz, E., Fonio, C., & Bazán, C. (2023). Subclinical inflammation biomarkers in an infant-juvenile patients with type 1 diabetes. Journal of the Argentine Society of Diabetes, 49(2), 44–49. https://doi.org/10.47196/diab.v49i2.199

Issue

Vol. 49 No. 2 (2015): May/Agost 2015

Section

Original article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.